Traditional drug design often takes more than ten years and costs about 2.6 billion dollars to bring an average drug to the market. Artificial intelligence (AI), including machine learning, has been making remarkable strides in many different fields, particularly drug discovery. In the past few years, a number of AI-powered models for understanding biological mechanisms have been more effective and efficient than the classical approaches. To document various advances in the field, the journal Computational and Mathematical Biophysics (CMB, https://www.degruyter.com/view/j/cmb) will publish a special issue on “Artificial Intelligence for Drug Design”.
Potential topics of this special include, but are not limited to:
· Drug design, screening, delivery
· Drug repurposing
· Structure-activity relationships
· Molecular modeling
· Structural biological studies
· Pharmacokinetics & toxicology
· Diagnostic technology
· Therapeutic medicine
· Vaccine development
· Simulations and software development
Important Dates
Manuscript due: September 1, 2022
First round of reviews: October 15, 2022
Anticipated publication date: December 21, 2022
Guest editors
Dr. Duc Nguyen (Lead), University of Kentucky, USA
Dr. Kelin Xia, Nanyang Technological University, Singapore
Dr. Kaifu Gao, Michigan State University, USA
Dr. Min-Chun Wu, Nanyang Technological University, Singapore
More information about this special issue can be found in https://www.degruyter.com/publication/journal_key/CMB/downloadAsset/CMB_CFP%20Artificial%20Intelligence%20for%20Drug%20Design.pdf. Prospective authors should submit their manuscript online at https://www.editorialmanager.com/mlbmb/default.aspx.
